Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer

被引:36
|
作者
Zeng, Hao [1 ,2 ]
Chen, Linyan [1 ,2 ]
Zhang, Mingxuan [3 ]
Luo, Yuling [3 ]
Ma, Xuelei [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy,State Key Lab Biotherapy, Chengdu, Peoples R China
[2] Collaborat Innovat Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
关键词
Ovarian cancer; Histopathology; Genomics; Transcriptomics; Proteomics; MUTATIONS; BRCA1; CARCINOMA; SURVIVAL;
D O I
10.1016/j.ygyno.2021.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. This study used histopathological image features to predict molecular features, and combined with multi-dimensional omics data to predict overall survival (OS) in high-grade serous ovarian cancer (HGSOC). Methods. Patients from The Cancer Genome Atlas (TCGA) were distributed into training set (n = 115) and test set (n = 114). In addition, we collected tissue microarrays of 92 patients as an external validation set. Quan-titative features were extracted from histopathological images using CellProfiler, and utilized to establish predic-tion models by machine learning methods in training set. The prediction performance was assessed in test set and validation set. Results. The prediction models were able to identify BRCA1 mutation (AUC = 0.952), BRCA2 mutation (AUC = 0.912), microsatellite instability-high (AUC = 0.919), microsatellite stable (AUC = 0.924), and molecular subtypes: proliferative (AUC = 0.961), differentiated (AUC = 0.952), immunoreactive (AUC = 0.941), mesenchymal (AUC = 0.918) in test set. The prognostic model based on histopathological image features could predict OS in test set (5-year AUC = 0.825) and validation set (5-year AUC = 0.703). We next explored the integrative prognostic models of image features, genomics, transcriptomics and proteomics. In test set, the models combining two omics had higher prediction accuracy, such as image features and genomics (5-year AUC = 0.834). The multi-omics model including all features showed the best prediction performance (5-year AUC = 0.911). According to risk score of multi-omics model, the high-risk and low-risk groups had significant survival differences (HR = 18.23, p < 0.001). Conclusions. These results indicated the potential ability of histopathological image features to predict above molecular features and survival risk of HGSOC patients. The integration of image features and multi-omics data may improve prognosis prediction in HGSOC patients. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 50 条
  • [32] Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis
    Su, Hao
    Jin, Yueqi
    Tao, Changyu
    Yang, Hua
    Yang, Ence
    Zhang, Wei-Guang
    Feng, Fengzhi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (04)
  • [33] Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
    Li-yuan Feng
    Bing-bing Yan
    Yong-zhi Huang
    Li Li
    Clinical Epigenetics, 2021, 13
  • [34] Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
    Feng, Li-yuan
    Yan, Bing-bing
    Huang, Yong-zhi
    Li, Li
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [35] Paraneoplastic Cerebellar Ataxia Can Affect Prognosis in High-Grade Serous Ovarian Cancer: A Case Report
    Liapi, Aikaterini
    Sarivalasis, Apostolos
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 1006 - 1012
  • [36] Effect of different metastasis patterns on the prognosis of patients with stage III high-grade serous ovarian cancer
    Yang, Hongjuan
    Gao, Dongmei
    Wang, Chang
    Jiao, Jinwen
    Yu, Xinping
    Li, Xiangkun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (08): : 3599 - 3606
  • [37] The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer
    Xu, Xia
    Deng, Fei
    Lv, Mengmeng
    Chen, Xiaoxiang
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (02) : 451 - 458
  • [38] Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
    Lheureux, Stephanie
    Lai, Zhongwu
    Dougherty, Brian A.
    Runswick, Sarah
    Hodgson, Darren R.
    Timms, Kirsten M.
    Lanchbury, Jerry S.
    Kaye, Stan
    Gourley, Charlie
    Bowtell, David
    Kohn, Elise C.
    Scott, Claire
    Matulonis, Ursula
    Panzarella, Tony
    Karakasis, Katherine
    Burnier, Julia V.
    Gilks, C. Blake
    O'Connor, Mark J.
    Robertson, Jane D.
    Ledermann, Jonathan
    Barrett, J. Carl
    Ho, Tony W.
    Oza, Amit M.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4086 - 4094
  • [39] Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients
    Kamieniak, Marta M.
    Rico, Daniel
    Milne, Roger L.
    Munoz-Repeto, Ivan
    Ibanez, Kristina
    Grillo, Miguel A.
    Domingo, Samuel
    Borrego, Salud
    Cazorla, Alicia
    Garcia-Bueno, Jose M.
    Hernando, Susana
    Garcia-Donas, Jesus
    Hernandez-Agudo, Elena
    Ramon y Cajal, Teresa
    Robles-Diaz, Luis
    Marquez-Rodas, Ivan
    Cusido, Maite
    Saez, Raquel
    Lacambra-Calvet, Carmen
    Osorio, Ana
    Urioste, Miguel
    Cigudosa, Juan C.
    Paz-Ares, Luis
    Palacios, Jose
    Benitez, Javier
    Garcia, Maria J.
    MOLECULAR ONCOLOGY, 2015, 9 (02) : 422 - 436
  • [40] Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
    Stiegeler, Nadja
    Garsed, Dale W.
    Au-Yeung, George
    Bowtell, David D. L.
    Heinzelmann-Schwarz, Viola
    Zwimpfer, Tibor A.
    FRONTIERS IN ONCOLOGY, 2024, 14